OPC-34712
Major Depressive Disorder
Phase 2Active
Key Facts
About Otsuka Holdings
Otsuka Holdings Co., Ltd. is a multinational pharmaceutical and healthcare company founded in 1964, headquartered in Tokyo, Japan. The company has built a strong reputation in central nervous system disorders, with major commercial successes including the antipsychotic Abilify and depression treatment Rexulti. Otsuka operates globally with a focus on innovation in psychiatry, neurology, oncology, and nephrology, maintaining a robust pipeline of novel therapeutics and a commitment to addressing unmet medical needs.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| HS-20089 | Hansoh Pharma | Phase 3 |
| Auvelity (AXS-05) | Axsome Therapeutics | Approved |
| Trintellix/Brintellix (vortioxetine) | Lundbeck | Approved/Commercial |